Startup profile · funding coverage
EnVision Endoscopy funding, valuation and investors
FDA-cleared SimpleStitch system for endoscopic tissue closure on standard flexible scopes.
Verified company research · funding, investors and latest developments
Keep track of EnVision Endoscopy
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Series A
$11.5M · November 10, 2026
Latest known valuation
Undisclosed
Series A · November 10, 2026
Total disclosed equity funding
$12M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
series a · Waltham, Massachusetts, USA
Investors in latest funding
Lead: Puma Venture Capital
Other: UTEC – University of Tokyo Edge Capital , Olympus Corporation of the Americas , MassVentures
Overview
Waltham, Massachusetts medtech developer behind SimpleStitch, a suturing system intended to simplify closure of tissue defects during gastrointestinal endoscopy with commonly used flexible scopes. It received FDA clearance in 2025 and began a limited US release in 2026. Puma Venture Capital led the November 2026 $11.5M Series A, with UTEC, Olympus Corporation of the Americas and MassVentures participating.
Why EnVision Endoscopy is interesting
November 10, 2026 $11.5M Series A coincides with the first 50 patient procedures at pilot sites, following FDA clearance in 2025 and limited US market release in 2026; early case count is not proof of wide adoption or comparative clinical superiority.
Product & use cases
Illustrative clinical buyer/operator workflow: (1) hospital or endoscopy center assesses scope compatibility, clearance and purchasing terms; (2) GI endoscopist receives device-specific training; (3) the physician performs a indicated endoscopic procedure using a standard flexible scope; (4) uses SimpleStitch for tissue closure when clinically appropriate; (5) monitors patient outcomes and records procedure quality. The vendor says 50 patient procedures were completed at pilot sites in 2026. Comparisons with alternative clips/suturing products, complication rates, long-term outcomes, device price and reimbursement economics are not established in the release.
- Closing selected tissue defects after advanced GI endoscopic procedures using a standard flexible endoscope.
- Endoscopy centers considering whether a simplified closure device can reduce specialized equipment requirements and training constraints.
Key facts
- Nov 10, 2026 $11.5M oversubscribed Series A led by Puma Venture Capital; participation UTEC, Olympus Corporation of the Americas, MassVentures.
- SimpleStitch received FDA clearance in 2025 and entered a limited US market release in 2026.
- 50 completed patient procedures at pilot sites were reported, but no independent complication, comparative efficacy or broader utilization rates were disclosed.
Funding history (newest first)
Series A
2026-11-10 $11.5M Valuation: Undisclosed- Puma Venture Capital (lead)
- UTEC – University of Tokyo Edge Capital (participant)
- Olympus Corporation of the Americas (participant)
- MassVentures (participant)
Source: Read source · prnewswire.com
Competitive landscape
Edge: The vendor positions SimpleStitch between conventional clips and advanced endoscopic suturing, using standard flexible endoscopes. This is a stated product positioning, not a verified superiority claim.
Buyers should compare actual FDA indications, scope compatibility, reimbursement, procedural learning curves, closure durability, procedure time, adverse events and price. First 50 reported procedures support early experience, not statistically established superiority.
-
Boston Scientific Resolution clips alternative
Endoscopic mechanical clipping; different tissue-closure applications and limitations.
-
Apollo Endosurgery OverStitch direct
Established endoscopic suturing alternative; device compatibility and training burden should be compared.
-
Medtronic GI closure devices adjacent
Broader gastrointestinal procedural closure market.
Market / IPO context
Editorial / static context — not a live quote.
FAQs about EnVision Endoscopy
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.